Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
Collaboration supports multiple discovery efforts, including vaccines
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Orion to receive an upfront payment of USD 290 million
She joins Enveda from Gilead Sciences
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Based on a post hoc analysis, fewer required respiratory interventions
Subscribe To Our Newsletter & Stay Updated
